Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
Addictive Behaviors|March 3, 2019
Mediation analysis with zero-inflated substance use outcomes: Challenges and recommendationsHolly P O'Rourke, Edwin VazquezAmerican Journal of Physiology. Heart and Circulatory Physiology|April 12, 2005
Structural differences in two biochemically defined populations of cardiac mitochondriaAlessandro Riva, Bernard Tandler, Felice Loffredo, et al.Scientific Reports|August 4, 2016
Pre-Clinical Study of a Novel Recombinant Botulinum Neurotoxin Derivative Engineered for Improved SafetyEdwin Vazquez-Cintron, Luis Tenezaca, Christopher Angeles, et al.Mechanisms of Ageing and Development|November 15, 2006
Structure of cristae in cardiac mitochondria of aged ratAlessandro Riva, Bernard Tandler, Edward J Lesnefsky, et al.Clinical & Developmental Immunology|December 13, 2006
The Wnt signaling antagonist Kremen1 is required for development of thymic architectureMasako Osada, Emi Ito, Hector A Fermin, et al.JCI Insight|January 31, 2020
Symptomatic treatment of botulism with a clinically approved small moleculeEdwin Vazquez-Cintron, James Machamer, Celinia Ondeck, et al.Journal of Neurochemistry|September 16, 2025
Botulinum Neurotoxin A Signaling in Pain Modulation Within Human Sensory NeuronsKatherin A Gabriel, Kali Hankerd, Paulino Barragan-Iglesias, et al.Cell Reports|February 27, 2020
Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum NeurotoxinsKwok-Ho Lam, Jacqueline M Tremblay, Edwin Vazquez-Cintron, et al.American Journal of Physiology. Heart and Circulatory Physiology|June 12, 2004
Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidationMargaret P Chandler, Janos Kerner, Hazel Huang, et al.Toxins|September 29, 2020
Camelid VHH Antibodies that Neutralize Botulinum Neurotoxin Serotype E Intoxication or Protease FunctionJacqueline M Tremblay, Edwin Vazquez-Cintron, Kwok-Ho Lam, et al.Pageof 2